Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy

NCT06552572 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG: Glofitamab

Sponsor

Samsung Medical Center